1 / 7

Pharmacology2 Edarbi

Pharmacology2 Edarbi. Prep by: Al’a Barakat Dir by: Dr Adham Abu Taha. Edabri (antihypertensive drug). Generic name: Azilsartan medoxomil Made by: Takeda Pharmaceutical North America of Deerfield,I11 Date of approval: February ,25,2011

amaryllis
Download Presentation

Pharmacology2 Edarbi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacology2Edarbi Prep by: Al’aBarakat Dir by: Dr Adham Abu Taha

  2. Edabri (antihypertensive drug) • Generic name: Azilsartan medoxomil • Made by: Takeda Pharmaceutical North America of Deerfield,I11 • Date of approval: February ,25,2011 • US FAD approved edarbi to treat high blood pressure in adult. • More effective in lowering 24_houre pressure than valsartan and olmesartan.

  3. MOA: _It blocks the vasoconstrictor & aldosterone secreting effect of angiotensin II by it’s selective blocking to AT1 receptor in many tissue, such as vascular smooth muscle and the adrenal gland, so leads to vasodilation and increase the excretion of Na with urine (water passively follows Na) decrease the blood pressure _It doesn’t block any ion channel or other receptors. _ Because azilsartan doesn’t inhibit ACE it will not affect the bradykinin level.

  4. - rote of administration: only orally -Azilsartanmedoxomil is a prodrughydrolyzed in the GIT during absorption into azilsartanby CYP2C9. -Bioavailability of Edrabi is 60%. -Cmax after oral administration reached after 1.5_3 hours. -Plasma half life 11hours,clearance about 2.3 ml/min (in urine & feces) . -It can cross the placenta and reach the fetus, very small amounts cross the BBB. pharmacodynamic : -Azilsartan inhibit the presser effects of angiotensin II in a dose related manner. -Increase the plasma concentrations of angiotensin I,II &renin . and decrease the concentration of aldosterone -No effects on the levels of K & Na absorved. pharmacokinetic:

  5. Adverse effect of Edarbi(mild ,notdose, age & gender related): • GIT: nausea ,diarrhea . • CNS: dizziness. • Respiratory: cough . • Muscle: muscle spasm. • Hypotension is the most serious one which may lead to discontinuation.

  6. Drug interactions: -If Edarbi taken with COX II inhibitors may result in deterioration of the renal function acute renal failure (reversible) . • COX II inhibitors attenuate the anti hypertensive effect of Edarbi. Warning and precautions: Edarbishouldn’t be taken by: - The pregnant women especially in the 2nd & 3rd trimester injury& death in the fetus. -Hypotension in volume or salt depleted patients. -patient with impaired renal function.

More Related